

Sponsor

Novartis

Generic Drug Name

Asciminib

Trial Indication(s)

Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Protocol Number

CABL001A0US12

Protocol Title

Treatment Patterns and Key Endpoints among Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Community Oncology Setting

For information on the study results please follow the link:

[Real-World Treatment Patterns and Molecular Response \(MR\) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia \(CML-CP\) in a Large Community Oncology Setting | Blood | American Society of Hematology](#)